TP53 and prostate cancer: Since PC-3 cells are p53-null58 and MDA-MB-231 cells have mutant p535, our results in terms of cell viability are broadly consistent with the study of Ben Sahra et al., who demonstrated that the combination of 2-DG and metformin does not reduce viability of prostate cancer cells deficient or mutated for p5346.